# Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

> **NCT03579654** · PHASE2 · UNKNOWN · sponsor: **OncBioMune Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Proscavax

## Key facts

- **NCT ID:** NCT03579654
- **Lead sponsor:** OncBioMune Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-28
- **Primary completion:** 2021-02-28
- **Final completion:** 2022-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579654, "Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03579654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*